 |
市場調查報告書
商品編碼
1621655
血癌診斷市場機會、成長動力、產業趨勢分析與預測 2024 - 2032Blood Cancer Diagnostics Market Opportunity, Growth Drivers, Industry Trend Analysis, and Forecast 2024 - 2032 |
||||||
2023 年全球血癌診斷市場價值為 124 億美元，預計 2024 年至 2032 年複合年成長率為 6.8%。淋巴系統。市場成長的主要驅動力之一是全球血癌發生率的上升。隨著越來越多的人接受白血病、淋巴瘤和骨髓瘤等疾病的診斷，對有效診斷工具的需求激增。盛行率的增加可歸因於多種因素，包括人口老化、遺傳傾向和環境影響。
血癌診斷市場按測試類型細分，包括分子測試、血液檢查、影像測試和活體組織切片。血液檢測佔據了市場的很大一部分，到 2023 年約佔 47 億美元。此外，該市場按最終用途分類，包括醫院、診斷實驗室、影像中心和癌症研究機構。到 2032 年，醫院領域預計將達到 90 億美元。
對尖端診斷設備的大量投資以及對早期檢測和個人化治療策略的高度重視推動了這一趨勢。醫院的綜合醫療保健系統促進了高效的患者管理和跨多個部門的協調護理，進一步鞏固了其在血癌診斷中的關鍵作用。在美國，到 2032 年，血癌診斷市場預計將成長至約 94 億美元。這種積極主動的方法提高了患者的生存率，同時推動了對診斷測試和技術的需求，從而促進了區域市場的成長。
| 市場範圍 | |
|---|---|
| 開始年份 | 2023年 |
| 預測年份 | 2024-2032 |
| 起始值 | 124 億美元 |
| 預測值 | 222億美元 |
| 複合年成長率 | 6.8% |
此外，用於加強支持血癌診斷和治療的基礎設施的公共和私人投資都對該行業的收入成長做出了重大貢獻。
目錄
第 1 章：方法與範圍
第 2 章：執行摘要
第 3 章：產業洞察
- 產業生態系統分析
- 產業影響力
- 成長動力
- 血癌盛行率上升
- 癌症診斷技術的進步
- 提高認知和早期篩檢計劃
- 產業陷阱與挑戰
- 先進診斷的高成本
- 嚴格的監管場景
- 成長動力
- 成長潛力分析
- 監管環境
- 技術景觀
- 核心技術
- 鄰近技術
- 未來市場趨勢
- 差距分析
- 波特的分析
- 杵分析
第 4 章：競爭格局
- 介紹
- 公司市佔率分析
- 公司矩陣分析
- 主要市場參與者的競爭分析
- 競爭定位矩陣
- 戰略儀表板
第 5 章：市場估計與預測：按產品分類，2021 - 2032 年
- 主要趨勢
- 儀器儀表
- 檢測試劑盒和試劑
第 6 章：市場估計與預測：按測試類型，2021 - 2032 年
- 主要趨勢
- 血液檢查
- 影像學檢查
- 活體組織切片
- 分子測試
第 7 章：市場估計與預測：按癌症類型，2021 - 2032 年
- 主要趨勢
- 白血病
- 淋巴瘤
- 骨髓瘤
第 8 章：市場估計與預測：按最終用途，2021 - 2032 年
- 主要趨勢
- 醫院
- 診斷實驗室
- 診斷影像中心
- 癌症研究機構
第 9 章：市場估計與預測：按地區，2021 - 2032
- 主要趨勢
- 北美洲
- 美國
- 加拿大
- 歐洲
- 德國
- 英國
- 法國
- 西班牙
- 義大利
- 荷蘭
- 歐洲其他地區
- 亞太地區
- 中國
- 日本
- 印度
- 澳洲
- 韓國
- 亞太地區其他地區
- 拉丁美洲
- 巴西
- 墨西哥
- 阿根廷
- 拉丁美洲其他地區
- 中東和非洲
- 南非
- 沙烏地阿拉伯
- 阿拉伯聯合大公國
- 中東和非洲其他地區
第 10 章：公司簡介
- Abbott Laboratories
- Alercell, Inc.
- Becton, Dickinson and Company
- Bio-Rad Laboratories, Inc.
- Bio-Techne Corporation
- Danaher Corporation
- F. Hoffmann-La Roche Ltd
- GE HealthCare Technologies Inc.
- HORIBA, Ltd.
- Illumina, Inc.
- Invivoscribe, Inc.
- QIAGEN NV
- Sysmex Corporation
- Thermo Fisher Scientific Inc.
The Global Blood Cancer Diagnostics Market was valued at USD 12.4 billion in 2023 and is projected to grow at a CAGR of 6.8% between 2024 and 2032. Blood cancer diagnostics encompasses various tests and procedures designed to diagnose, detect, and monitor cancers affecting the bone marrow, blood, and lymphatic system. One of the primary drivers of market growth is the rising incidence of blood cancers worldwide. As more individuals receive diagnoses for conditions like leukemia, lymphoma, and myeloma, the demand for effective diagnostic tools has surged. This increase in prevalence can be attributed to several factors, including an aging population, genetic predispositions, and environmental influences.
The blood cancer diagnostics market is segmented by test type, including molecular tests, blood tests, imaging tests, and biopsies. Blood tests represent a substantial portion of the market, accounting for around USD 4.7 billion in 2023. These tests are a cornerstone in the early detection and monitoring of blood cancers due to their affordability and quick turnaround time, making them a favored option among healthcare professionals. Additionally, the market is categorized by end-use, comprising hospitals, diagnostic laboratories, imaging centers, and cancer research institutes. The hospital segment is expected to reach USD 9 billion by 2032. Hospitals are increasingly incorporating advanced diagnostic technologies to enhance the precision and speed of blood cancer detection.
This trend is fueled by significant investments in cutting-edge diagnostic equipment and a strong focus on early detection and personalized treatment strategies. The integrated healthcare systems found in hospitals facilitate efficient patient management and coordinated care across multiple departments, further solidifying their crucial role in blood cancer diagnostics. In the United States, the blood cancer diagnostics market is anticipated to grow to approximately USD 9.4 billion by 2032. There is a notable emphasis on early detection and prevention of blood cancers, with healthcare providers and government entities advocating for routine screenings and early diagnoses. This proactive approach improves patient survival rates while driving demand for diagnostic tests and technologies, boosting the regional market growth.
| Market Scope | |
|---|---|
| Start Year | 2023 |
| Forecast Year | 2024-2032 |
| Start Value | $12.4 Billion |
| Forecast Value | $22.2 Billion |
| CAGR | 6.8% |
Furthermore, both public and private investments to enhance the infrastructure to support blood cancer diagnosis and treatment contribute significantly to revenue growth in this sector.
Table of Contents
Chapter 1 Methodology & Scope
- 1.1 Market scope & definitions
- 1.2 Research design
- 1.2.1 Research approach
- 1.2.2 Data collection methods
- 1.3 Base estimates & calculations
- 1.3.1 Base year calculation
- 1.3.2 Key trends for market estimation
- 1.4 Forecast model
- 1.5 Primary research and validation
- 1.5.1 Primary sources
- 1.5.2 Data mining sources
Chapter 2 Executive Summary
- 2.1 Industry 360° synopsis
Chapter 3 Industry Insights
- 3.1 Industry ecosystem analysis
- 3.2 Industry impact forces
- 3.2.1 Growth drivers
- 3.2.1.1 Rising prevalence of blood cancer
- 3.2.1.2 Advancements in cancer diagnostic technologies
- 3.2.1.3 Growing awareness and early screening programs
- 3.2.2 Industry pitfalls & challenges
- 3.2.2.1 High cost of advanced diagnostics
- 3.2.2.2 Stringent regulatory scenario
- 3.2.1 Growth drivers
- 3.3 Growth potential analysis
- 3.4 Regulatory landscape
- 3.5 Technology landscape
- 3.5.1 Core technologies
- 3.5.2 Adjacent technologies
- 3.6 Future market trends
- 3.7 Gap analysis
- 3.8 Porter's analysis
- 3.9 PESTLE analysis
Chapter 4 Competitive Landscape, 2023
- 4.1 Introduction
- 4.2 Company market share analysis
- 4.3 Company matrix analysis
- 4.4 Competitive analysis of major market players
- 4.5 Competitive positioning matrix
- 4.6 Strategy dashboard
Chapter 5 Market Estimates and Forecast, By Product, 2021 - 2032 ($ Mn)
- 5.1 Key trends
- 5.2 Instruments
- 5.3 Assay kits and reagents
Chapter 6 Market Estimates and Forecast, By Test Type, 2021 - 2032 ($ Mn)
- 6.1 Key trends
- 6.2 Blood tests
- 6.3 Imaging tests
- 6.4 Biopsy
- 6.5 Molecular tests
Chapter 7 Market Estimates and Forecast, By Cancer Type, 2021 - 2032 ($ Mn)
- 7.1 Key trends
- 7.2 Leukemia
- 7.3 Lymphoma
- 7.4 Myeloma
Chapter 8 Market Estimates and Forecast, By End Use, 2021 - 2032 ($ Mn)
- 8.1 Key trends
- 8.2 Hospitals
- 8.3 Diagnostic laboratories
- 8.4 Diagnostic imaging centers
- 8.5 Cancer research institutes
Chapter 9 Market Estimates and Forecast, By Region, 2021 - 2032 ($ Mn)
- 9.1 Key trends
- 9.2 North America
- 9.2.1 U.S.
- 9.2.2 Canada
- 9.3 Europe
- 9.3.1 Germany
- 9.3.2 UK
- 9.3.3 France
- 9.3.4 Spain
- 9.3.5 Italy
- 9.3.6 Netherlands
- 9.3.7 Rest of Europe
- 9.4 Asia Pacific
- 9.4.1 China
- 9.4.2 Japan
- 9.4.3 India
- 9.4.4 Australia
- 9.4.5 South Korea
- 9.4.6 Rest of Asia Pacific
- 9.5 Latin America
- 9.5.1 Brazil
- 9.5.2 Mexico
- 9.5.3 Argentina
- 9.5.4 Rest of Latin America
- 9.6 Middle East and Africa
- 9.6.1 South Africa
- 9.6.2 Saudi Arabia
- 9.6.3 UAE
- 9.6.4 Rest of Middle East and Africa
Chapter 10 Company Profiles
- 10.1 Abbott Laboratories
- 10.2 Alercell, Inc.
- 10.3 Becton, Dickinson and Company
- 10.4 Bio-Rad Laboratories, Inc.
- 10.5 Bio-Techne Corporation
- 10.6 Danaher Corporation
- 10.7 F. Hoffmann-La Roche Ltd
- 10.8 GE HealthCare Technologies Inc.
- 10.9 HORIBA, Ltd.
- 10.10 Illumina, Inc.
- 10.11 Invivoscribe, Inc.
- 10.12 QIAGEN N.V.
- 10.13 Sysmex Corporation
- 10.14 Thermo Fisher Scientific Inc.
